ADAP News and Press, Adaptimmune Therapeutics plc From 09/09/19

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SPE...

Adaptimmune (NASDAQ: ADAP ) inks an agreement with Tokyo-based Noile-Immune Biotech to co-develop next-generation SPEAR T-cell products incorporating the latter's PRIME (proliferation-inducing and migration-enhancing) technology to augment CAR-T cell activity. More news on: Adaptimmune T...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovative cancer immu...

Adaptimmune Therapeutics plc (ADAP) Q2 2019 Results Conference Call August 01, 2019 08:00 AM ET Company Participants Juli Miller - IR James Noble - CEO Adrian Rawcliffe - Incoming CEO Rafael Amado - President, R&D Conference Call Participants Waleed Abdel-Naby - SunTr...

Thinly traded micro cap Adaptimmune ( ADAP -17.3% ) is down on more than double normal volume, albeit on turnover of only 674K shares, in apparent response to its Q2 report released today. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, Read ...

Stericycle (NASDAQ: SRCL ) upgraded to Neutral with a $44 (flat) price target at Baird. More news on: Stericycle, Inc., Abiomed, Inc., Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, , Read more ...

Adaptimmune (NASDAQ: ADAP ): Q2 GAAP EPS of -$0.07 beats by $0.29 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...

- Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients – - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer Center - - Started SURPASS trial – the first next-generation clinical trial with ADP-A2M4CD8 ...

- Adrian Rawcliffe to assume CEO role from September 1, 2019 - - John Lunger promoted to Chief Patient Supply Officer from August 1, 2019, as Adaptimmune gears up for commercial delivery of products to patients – - Rafael Amado, President R&D, will leave the Company on Augus...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update before the U.S. markets open on Thu...